AKBA - Company ID 0001517022
The table below shows Akebia Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $211.65M | $294.64M |
| Cost of revenue | $39.46M | $63.18M | $74.15M | $85.57M | $150.67M | $296.48M |
| Gross profit | - | - | - | - | - | - |
| R&D | $62.36M | $37.65M | $63.08M | $129.99M | $147.85M | $218.49M |
Akebia Therapeutics, Inc. reported annual revenue of $236.20M for fiscal year 2025. That is up 47.5% from $160.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.53M (FY 2016) to $236.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $107.48M |
| $106.55M |
| $100.23M |
| $138.60M |
| $174.14M |
| $154.10M |
| Operating income | $23.50M | -$50.47M | -$46.26M | -$80.78M | -$264.50M | -$377.83M |
| Income tax | $1.62M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$5.30M | -$69.40M | -$51.90M | -$94.20M | -$282.00M | -$384.84M |
| EPS (diluted) | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 |